HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chuntharapai, A. Articles by Kim, K. J. Search for Related Content PubMed PubMed Citation Articles by Chuntharapai, A. Articles by Kim, K. J.

Determination of Residues Involved in Ligand Binding and Signal Transmission in the Human IFN- Receptor 2

A. Chuntharapai^*, V. Gibbs, J. Lu^*, A. Ow, S. Marsters^*, A. Ashkenazi^*, A. De Vos^* and K. Jin Kim^1,*

^* Departments of Antibody Technology, Molecular Oncology, and Protein Engineering, Genentech Inc., South San Francisco, CA 94080; and Department of Surgery, San Francisco Veterans Affairs Medical Center, San Francisco, CA 94121

The human IFN- receptor (hIFNAR) is a complex composed of at least two chains, hIFNAR1 and hIFNAR2. We have performed a structure-function analysis of hIFNAR2 extracellular domain regions using anti-hIFNAR2 mAbs (1D3, 1F3, and 3B7) and several type I human IFNs. These mAbs block receptor activation, as determined by IFN-stimulated gene factor 3 formation, and block the antiviral cytopathic effects induced by type I IFNs. We generated alanine substitution mutants of hIFNAR2-IgG and determined that regions of hIFNAR2 are important for the binding of these blocking mAbs and hIFN-2/1. We further demonstrated that residues E78, W101, I104, and D105 are crucial for the binding of hIFN-2/1 and form a defined protrusion when these residues are mapped upon a structural model of hIFNAR2. To confirm that residues important for ligand binding are indeed important for IFN signal transduction, we determined the ability of mouse L929 cells expressing hIFNAR2 extracellular domain mutants to mediate hIFN signal. hIFN-8, previously shown to signal a response in L929 cells expressing hIFNAR1, was unable to signal in L929 cells expressing hIFNAR2. Transfected cells expressing hIFNAR2 containing mutations at residues E78, W101, I104, or D105 were unresponsive to hIFN-2, but remained responsive to hIFN-ß. In summary, we have identified specific residues of hIFNAR2 important for the binding to hIFN-2/1 and demonstrate that specific regions of the IFNAR interact with the subspecies of type I IFN in different manners.

This article has been cited by other articles:

				V. S. Cull, P. A. Tilbrook, E. J. Bartlett, N. L. Brekalo, and C. M. James Type I interferon differential therapy for erythroleukemia: specificity of STAT activation Blood, April 1, 2003; 101(7): 2727 - 2735. [Abstract] [Full Text] [PDF]

				L. C. Roisman, J. Piehler, J.-Y. Trosset, H. A. Scheraga, and G. Schreiber Structure of the interferon-receptor complex determined by distance constraints from double-mutant cycles and flexible docking PNAS, November 6, 2001; 98(23): 13231 - 13236. [Abstract] [Full Text] [PDF]

				C. Barthe, F.-X. Mahon, M.-J. Gharbi, C. Faberes, C. Bilhou-Nabera, A. Hochhaus, J. Reiffers, and G. Marit Expression of interferon-{alpha} (IFN-{alpha}) receptor 2c at diagnosis is associated with cytogenetic response in IFN-{alpha}-treated chronic myeloid leukemia Blood, June 1, 2001; 97(11): 3568 - 3573. [Abstract] [Full Text] [PDF]

				A. Chuntharapai, K. Dodge, K. Grimmer, K. Schroeder, S. A. Marsters, H. Koeppen, A. Ashkenazi, and K. J. Kim Isotype-Dependent Inhibition of Tumor Growth In Vivo by Monoclonal Antibodies to Death Receptor 4 J. Immunol., April 15, 2001; 166(8): 4891 - 4898. [Abstract] [Full Text] [PDF]